updated 6/22/20 The GIST Risk Calculator is based on research from Dr. Heikki Joensuu, Professor of Oncology at the University of Helsinki and the Research Director at the Helsinki Comprehensive Cancer Center, and his colleagues. The [...]
David Josephy On behalf of The Life Raft Group USA and Life Raft Group Canada, I attended the Sarcoma & GIST 2016 meeting organized by the European Society for Medical Oncology (ESMO) [...]
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
In a recent article entitled "Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions" published online in Springer for Research and Development, LRG Research Team member Sebastian Bauer [...]
In a recent article in the May 2015 edition of the European Journal of Cancer, Heikki Joensuu, one of the foremost authorities on adjuvant treatment for GIST, discussed how follow-up treatment is currently performed for [...]
Some stomach GISTs smaller than 2 cm may pose more risk than previously thought according to a new report from China.
Radiation therapy has been revisited as an option in GIST treatment. Keep reading to learn more about the research that has gone into radiation therapy.
Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.